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348REPLY: Drug-Coated Balloon Treatment as
Default Strategy for DES-ISRWe appreciate the interest of Dr. Scheller and col-
leagues in our randomized study comparing
everolimus-eluting stents (EES) with drug-eluting
balloons (DEB) in patients with drug-eluting stent
(DES) in-stent restenosis (ISR) (1). Scheller et al. (2)
pioneered the preclinical and clinical studies
demonstrating the efﬁcacy of DEB in patients with
ISR. However, we respectfully disagree with some
interpretations of our ﬁndings.
First, the RIBS IV (Restenosis Intra-stent of Drug-
Eluting Stents: Paclitaxel-eluting Balloon vs Ever-
olimus-eluting Stent) trial investigators are experts in
the treatment of ISR. Indeed, for the last 15 years,
this group has been focusing on the treatment of
this condition, using different strategies (1,3). In-
vestigators were well aware of the importance of
aggressively tackling under-expanded stents and
preventing geographic miss phenomena, issues that
were re-emphasized in the protocol (1,3). In our
study, immediate and late angiographic ﬁndings in
each arm were similar when results were compared in
centers lumped together by tertiles according to the
number of treated patients.
Second, optimization of ﬁnal results was system-
atically attempted, and the strategy of high-pressure
balloon dilation was performed in both arms (1,3). A
mean 18 bar was used in the DEB arm, and impor-
tantly, the balloon-to-artery ratio was larger in this
group. However, suboptimal initial results may still
occur after DEB. Indeed, 19 patients (12%) treated
with DEB had a residual stenosis of $30% (range:
30% to 41%) on quantitative angiography. We tried
to avoid crossover that was restricted to only 5 pa-
tients with signiﬁcant residual stenosis or type $C
dissections. Whether a more liberal crossover to
DES would beneﬁt a DEB strategy in this scenario
deserves further investigation. Moreover, the
mandated aggressive lesion predilation dissipates
any potential concern of signiﬁcant drug loss from
the DEB before inﬂation. Finally, the superior im-
mediate angiographic results of the EES are in line
with those of all previous studies comparing balloon
with stent-based strategies. Actually, the small dif-
ference in minimal lumen diameter after the proce-
dure (EES: 2.22 mm; DEB: 2.10 mm) was unexpected
and, if anything, would penalize the EES arm (2). We
believe that the challenging substrate of DES-ISR
explains the relatively poor angiographic results
obtained in both arms despite our optimization
efforts.Third, we designed the trial to prevent “oculo-
stenotic” reﬂex-inﬂuenced clinical outcomes. All
patients with reinterventions in the DCB arm had
ischemia or severely occlusive lesions, justifying the
procedure. However, operators were not blinded to
treatment allocation, and previous studies suggested
that reinterventions would be perceived as less
attractive in patients with ISR on a double-metal
layer (4). In our study, however, the 8 patients
with untreated ISR in the EES arm were completely
asymptomatic (1 patient had total vessel occlusion
and 7 “moderate” ISR [diameter stenosis: 53  3%;
minimal lumen diameter: 1.3  0.3 mm]). Thus, in
the EES arm, a signiﬁcantly larger minimal lumen
diameter and smaller diameter stenosis were ob-
tained at follow-up, and of the fewer patients
developing recurrent ISR, many were asymptomatic,
showing just moderate lesions that were left un-
treated (1).
Our ﬁndings conﬁrm the superior efﬁcacy of DEB in
patients with DES-ISR compared with that of previous
studies using more classical interventions. However,
in this challenging anatomic scenario, EES provided
better late angiographic ﬁndings and also a signiﬁcant
reduction in the need for reinterventions than DEB
(1). We fully agree that long-term safety and efﬁcacy
information on these novel interventions are urgently
needed. We also consider the “safety signal” favoring
DEB rather than “ﬁrst-generation” DES, detected in
some previous ISR trials at very late follow-up, to be
of major interest, but this should be interpreted with
caution as those studies were largely unpowered in
this regard (4). Currently, the real challenge remains
to identify the subgroup of patients with DES-ISR in
whom DEB will provide long-term results similar to
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2015;8:885–8.Atrial Fibrillation Is an
Obesity-Related Outcome,
Requiring a Body
Composition-Neutral
Assessment of
Cardiorespiratory FitnessWe read with interest the study by Pathak et al. (1) of
the role of exercise in the care of obese patients with
atrial ﬁbrillation (AF). The authors demonstrated
convincingly the compound beneﬁt of an “alliance
of cardiorespiratory ﬁtness with weight-loss” in pre-
venting recurrence of AF. We accept the validity of
the main conclusion but want to point out that the
ﬁtness test used cannot discriminate between effects
of ﬁtness gain and weight loss.
As stated recently, the treadmill protocol used for
estimating ﬁtness is likely to introduce a bias
against obese individuals (2). Brieﬂy, the most ac-
curate test of cardiorespiratory ﬁtness is direct
measurement of oxygen consumed in a maximal
exercise test. The indirect treadmill test that was
used in the current study is a simpliﬁed protocol for
clinical use (1). As in all weight-bearing forms of
exercise, obese individuals are at a disadvantage as
they have to carry more weight in the form of fat
that does not contribute to exercise performance.
Thus, other things being equal, the more obese
subjects will be exhausted earlier and their ﬁtness
estimated lower. Correction of a similar body
composition bias required appreciation of ﬁtness
estimates with increasing obesity by 17% to 39% (3).
In the current study, it is impossible to establish
whether ﬁtness can compensate for fatness as the
measure of ﬁtness (treadmill time) in itself is a
function of both ﬁtness and fatness.We fully agree with the authors that both weight
loss and physical exercise are essential components
of risk management in overweight and obese sub-
jects: Advocating a ﬁtness-ﬁrst approach (4), based on
treadmill test results similar to those in the current
study, might mislead the general public into turning a
blind eye to the importance of simultaneous dietary
weight management.*Benno Krachler, MD, PhD, MS
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382–90.REPLY: AtrialFibrillation IsanObesity-Related
Outcome, Requiring a Body
Composition-Neutral Assessment of
Cardiorespiratory FitnessWe thank Drs. Krachler and Lindahl for highlighting
some of the key ﬁndings of the CARDIO-FIT
(CARDIOrespiratory FITness on Arrhythmia Recur-
rence in Obese Individuals With Atrial Fibrillation)
study. This study demonstrated that, in overweight
and obese individuals with symptomatic atrial ﬁbril-
lation (AF), preserved baseline cardiorespiratory
ﬁtness (CRF) improves long-term freedom from AF.
Gain in CRF had a synergistic and additive effect on
weight loss in improving long-term outcome of AF (1).
The study determined CRF by using a commonly per-
formed, highly reproducible, and well-validated
“symptom limited treadmill test” (2). It is acknowl-
edged that metabolic equivalent (METs) calculation
and peak O2 consumption (gold standard) can vary
